Esmolol Adverse ReactionPhase 2/3NCT05850832
Efficacy of Esmolol Versus Magnesium Sulphate on Quality of Recovery in Patients Undergoing Laparoscopic Cholecystectomy: Randomized Controlled Study
A Phase 2/3 study testing Esmolol and Magnesium sulfate in people with Esmolol Adverse Reaction, run by Alexandria University at 1 site in Egypt.
Trial summary
sixty patients, of both sexes, of ASA I or II planned for ambulatory laparoscopic cholecystectomy under general anaesthesia were engaged into 2 groups. Esmolol group were given 1 mg/kg loading dose followed by 30 μg/kg/min throughout the surgery, whereas magnesium sulphate (MgSo4) group were given loading dose 40… Read more about this study
- Who is it for?
- Ages 20 to 65 years
- Conditions the study is for
- Esmolol Adverse Reaction
- What is being tested?
- Esmolol and Magnesium sulfate
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 5 Oct 2022to 10 Apr 2023
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- patients aged 20-65 years of both sexes
Who cannot join
- patients on chronic use or known allergic to the study drugs
- body mass index >35 kg/m2,
- significant organ dysfunction, cardiac dysrhythmias, neuromuscular diseases
- liver or renal disease,
- known asthma or reactive airway diseases.
Trial locations and contacts
1 site in 1 country.
About this study
sixty patients, of both sexes, of ASA I or II planned for ambulatory laparoscopic cholecystectomy under general anaesthesia were engaged into 2 groups. Esmolol group were given 1 mg/kg loading dose followed by 30 μg/kg/min throughout the surgery, whereas magnesium sulphate (MgSo4) group were given loading dose 40 mg/kg over 15 mins then maintenance dose 15 mg/kg/h till end of surgery. General anaesthesia was standardized and postoperative analgesia included fentanyl. Variables denoting immediate recovery from anaesthesia, pain score and time of stay in PACU were recorded. White-Song score ≥ 12 along with pain score < 4 were the cut off levels for patients' discharge from PACU.
Read the detailed description
The primary end point of this study are variables concerning immediate postoperative recovery like times needed for spontaneous eye opening, tongue protrusion, extubation and ability of the patient to mention name. Secondary outcomes includes pain assessment using pain numerical scale, time for first call to analgesia, total amount of intraoperative fentanyl consumption, total dose of rescue antiemetics and time of discharge from PACU.
Following attaining Ethical committee approval and patient's written consent- after broad explanation of the entire procedure- 60 patients aged 20-65 years of both sexes, of American society of Anesthesiologists (ASA) physical status I and II planned for ambulatory laparoscopic cholecystectomy under general anaesthesia were engaged to this study.
Exclusion criteria were: patients on chronic use or known allergic to the study drugs, body mass index >35 kg/m2, significant organ dysfunction, cardiac dysrhythmias, neuromuscular diseases, liver or renal disease, known asthma or reactive airway diseases.
Preoperatively all participants were carefully evaluated via detailed history taking, thorough physical examination and routine investigations (complete blood picture, renal function tests and liver functions). Also, they were instructed in the utilization of the verbal rating scale (VRS).
For blinding purpose, both the study drugs were prepared by an anaesthesiologist not enrolled in data assumption. Accordingly, for every case 2 prefilled syringes; one 10-ml for loading dose and the other 20-ml for maintenance infusion were given unidentified to the operating theater containing either Esmolol (Esmolol hydrochloride; Baxter Healthcare Corp., Deerfield, USA) or MgSo4 ( Egyptian international pharmaceutical indust., EYGPT).
Randomization was achieved prior to the study by means of randomization table prepared by computer software to assign the number of cases among the studied groups. Patients were randomly allocated using closed envelopes method into 2 equal groups (n=30 each):
- Group (E): (Esmolol group) received loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery.
- Group (M): (Magnesium sulphate group) received loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
Loading dose was given after fentanyl injection and before propofol induction. Maintenance dose was continued until the end of the procedure.
No premedication was offered. On arrival to the operating room, an intravenous cannula was placed and secured before induction of anaesthesia and all patients were attached to standard monitors including pulse oximetry, ECG, non- invasive blood pressure and end tidal carbon dioxide (ETCO2) monitor (Datex ohmeda S/5).
Anaesthesia was induced with 1 μg/kg fentanyl and 1.5 - 2 mg/kg propofol till cessation of verbal contact. Cisatracurium 0.15 mg/kg was used for neuromuscular relaxation and endotracheal intubation (via 8 or 8.5 mm for males, 7 or 7.5 mm for female patients, high-volume/low pressure portex endotracheal tubes). Soon after induction, in both groups IV dexamethasone 8 mg was given and 1 g paracetamol IV was infused over 15 mins. Anaesthesia was maintained with sevoflurane 1-2 % with 50 % oxygen in air. Increments of IV fentanyl 0.5 µg/kg was given for analgesia if systolic blood pressure or heart rate was increased by more than 20 % of baseline level, also incremental dose of cisatracurium 0.03 mg/kg was used to maintain muscle relaxation according to nerve stimulation. Patients were mechanically ventilated to maintain ETCO2 between 33-35 mmHg and an oxygen saturation of 98 %. The port sites were infiltrated by the surgical team with 3ml of 0.25% bupivacaine. Pneumoperitoneum with carbon dioxide was achieved, maintaining the intraabdominal pressure at 12 mm Hg throughout surgery. Patients were positioned in 30 degrees anti-Trendelenburg position and rotated toward the left side to facilitate exposure of the gall bladder. IV warmed 0.9 % NaCL was given during surgery at a rate 6 ml/kg/hr. If required, intraoperative hypotension (mean arterial blood pressure lower than 50 mm Hg) and bradycardia (heart rate < 40 bpm) were managed in both groups with i.v ephedrine and atropine respectively. At the end of surgery, patients were returned to the supine position and the Co2 left in the peritoneal cavity was expelled by abdominal compression slowly. 0.25 % bupivacaine was injected again at the surgical incisions. Esmolol and Mgso4 infusions were stopped and discarded at end of the procedure, which was marked at the end of skin closure and wound coverage. Anaesthesia was discontinued and 100 % oxygen was administrated. Reversal of muscle relaxants by i.v neostigmine 0.04-0.08 mg/kg and atropine 0.02 mg/kg, and then oral secretion was suctioned and the patients were extubated fully awake after return of the protective airway reflexes with full muscle power. Times passed from end of procedure till spontaneous eye opening (from cessation of infusions till spontaneous eye opening), extubation, tongue protrusion, and patient's ability to mention name were recorded. Duration of surgery (time from skin incision till end of procedure) and duration of anaesthesia (time from induction till shifting the patients from operating table to the PACU) were also recorded.
Patients were transferred to the postanesthesia care unit (PACU) where heart rate, arterial blood pressure, respiration, and temperature were continuously monitored by a nurse blind to the study deign to avoid bias. Postoperative pain management included 1 g of paracetamol IV at 8 hr. Assessed of postoperative pain was done using pain numerical rating scale (NRS) on immediate arrival to PACU and every 30 mins for the first 2 hours afterwards. NRS is a (0-10) scale, where (0) denotes no pain, whereas (10) refers to maximal pain imagined. Fentanyl (25 μg) IV was used when NRS exceeded 4. Times to first rescue analgesia and total amount of fentanyl consumed were recorded. Recue antiemetic ondansetron (4 mg) IV was given for nausea lasting > 5 min (persistent) or vomiting and repeated as required. Total dose of ondansetron was noted.
The White-song scoring system a more up to date quick track scoring framework incorporating fundamental fast track variables like physical steadiness, vitals and consciousness level has been proposed to evaluate the recovery profile. Furthermore it involved assessment of adverse events like postoperative pain and vomiting, which were unfortunately missed by the modified Aldrete score. A minimum score (12 / 14) should be established prior to patient safe fast-tracked. It was evaluated on immediate arrival to PACU and every 30 mins for the first 2 hours afterwards. Patients reached White-Song score 12 + NRS < 4 were discharged from PACU. Length of stay in PACU till discharge were also recorded
- Conditions
- Esmolol Adverse Reaction
- Being tested
- Esmolol, Magnesium sulfate
- Keywords
- cholecystectomy, recovery profile, opioid sparing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EsmololDrug
loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery.
Magnesium sulfateDrug
loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
| Study group | Role | What they receive |
|---|---|---|
| Group E | Active comparator | Esmolol group: patients received loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery Receives: Drug: Esmolol |
| Group M | Active comparator | Magnesium sulphate group: patients received loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery. Receives: Drug: Magnesium sulfate |
What is being measured
The primary outcome is the main question the study is designed to answer.
times needed for spontaneous eye opening
time passed from end of procedure until the patient open his eyes
Measured: immediately postoperative
Secondary outcomes (1)
total amount of intraoperative fentanyl consumption
total amount of intra-opertaive fentanyl consumed throughout the procedure
Measured: immediately postoperative
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 May 2023
- Study start5 Oct 2022
- Primary completion5 Jan 2023
- Study completion10 Apr 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Esmolol Adverse ReactionStudies of the same condition, open and under way.
- More trials run by Alexandria UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- 60 patients aged 20-65 years of both sexes, of American society of Anesthesiologists (ASA) physical status I and II planned for ambulatory laparoscopic cholecystectomy under general anaesthesia were engaged to this study. * Group (E): (Esmolol group) received loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery. * Group (M): (Magnesium sulphate group) received loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alexandria University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05850832
- Sponsor's protocol ID
- 0305810
- Status last verified
- Apr 2023
- First submitted
- 29 Apr 2023
- Last updated
- 9 May 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Esmolol Versus Magnesium Sulphate on Quality of Recovery in Patients Undergoing Laparoscopic Cholecystectomy: Randomized Controlled Study
- ClinicalTrials.gov ID
- NCT05850832
- Acronym / sponsor ID
- 0305810
- Conditions
- Esmolol Adverse Reaction
- Keywords
- cholecystectomy, recovery profile, opioid sparing
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Alexandria UniversityUniversity, hospital or other
- Study start
- 5 Oct 2022 (actual)
- Primary completion
- 5 Jan 2023 (actual)
- Study completion
- 10 Apr 2023 (actual)
- First posted
- 9 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
sixty patients, of both sexes, of ASA I or II planned for ambulatory laparoscopic cholecystectomy under general anaesthesia were engaged into 2 groups. Esmolol group were given 1 mg/kg loading dose followed by 30 μg/kg/min throughout the surgery, whereas magnesium sulphate (MgSo4) group were given loading dose 40 mg/kg over 15 mins then maintenance dose 15 mg/kg/h till end of surgery. General anaesthesia was standardized and postoperative analgesia included fentanyl. Variables denoting immediate recovery from anaesthesia, pain score and time of stay in PACU were recorded. White-Song score ≥ 12 along with pain score < 4 were the cut off levels for patients' discharge from PACU.
Detailed description
The primary end point of this study are variables concerning immediate postoperative recovery like times needed for spontaneous eye opening, tongue protrusion, extubation and ability of the patient to mention name. Secondary outcomes includes pain assessment using pain numerical scale, time for first call to analgesia, total amount of intraoperative fentanyl consumption, total dose of rescue antiemetics and time of discharge from PACU.
Following attaining Ethical committee approval and patient's written consent- after broad explanation of the entire procedure- 60 patients aged 20-65 years of both sexes, of American society of Anesthesiologists (ASA) physical status I and II planned for ambulatory laparoscopic cholecystectomy under general anaesthesia were engaged to this study.
Exclusion criteria were: patients on chronic use or known allergic to the study drugs, body mass index >35 kg/m2, significant organ dysfunction, cardiac dysrhythmias, neuromuscular diseases, liver or renal disease, known asthma or reactive airway diseases.
Preoperatively all participants were carefully evaluated via detailed history taking, thorough physical examination and routine investigations (complete blood picture, renal function tests and liver functions). Also, they were instructed in the utilization of the verbal rating scale (VRS).
For blinding purpose, both the study drugs were prepared by an anaesthesiologist not enrolled in data assumption. Accordingly, for every case 2 prefilled syringes; one 10-ml for loading dose and the other 20-ml for maintenance infusion were given unidentified to the operating theater containing either Esmolol (Esmolol hydrochloride; Baxter Healthcare Corp., Deerfield, USA) or MgSo4 ( Egyptian international pharmaceutical indust., EYGPT).
Randomization was achieved prior to the study by means of randomization table prepared by computer software to assign the number of cases among the studied groups. Patients were randomly allocated using closed envelopes method into 2 equal groups (n=30 each):
- Group (E): (Esmolol group) received loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery.
- Group (M): (Magnesium sulphate group) received loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
Loading dose was given after fentanyl injection and before propofol induction. Maintenance dose was continued until the end of the procedure.
No premedication was offered. On arrival to the operating room, an intravenous cannula was placed and secured before induction of anaesthesia and all patients were attached to standard monitors including pulse oximetry, ECG, non- invasive blood pressure and end tidal carbon dioxide (ETCO2) monitor (Datex ohmeda S/5).
Anaesthesia was induced with 1 μg/kg fentanyl and 1.5 - 2 mg/kg propofol till cessation of verbal contact. Cisatracurium 0.15 mg/kg was used for neuromuscular relaxation and endotracheal intubation (via 8 or 8.5 mm for males, 7 or 7.5 mm for female patients, high-volume/low pressure portex endotracheal tubes). Soon after induction, in both groups IV dexamethasone 8 mg was given and 1 g paracetamol IV was infused over 15 mins. Anaesthesia was maintained with sevoflurane 1-2 % with 50 % oxygen in air. Increments of IV fentanyl 0.5 µg/kg was given for analgesia if systolic blood pressure or heart rate was increased by more than 20 % of baseline level, also incremental dose of cisatracurium 0.03 mg/kg was used to maintain muscle relaxation according to nerve stimulation. Patients were mechanically ventilated to maintain ETCO2 between 33-35 mmHg and an oxygen saturation of 98 %. The port sites were infiltrated by the surgical team with 3ml of 0.25% bupivacaine. Pneumoperitoneum with carbon dioxide was achieved, maintaining the intraabdominal pressure at 12 mm Hg throughout surgery. Patients were positioned in 30 degrees anti-Trendelenburg position and rotated toward the left side to facilitate exposure of the gall bladder. IV warmed 0.9 % NaCL was given during surgery at a rate 6 ml/kg/hr. If required, intraoperative hypotension (mean arterial blood pressure lower than 50 mm Hg) and bradycardia (heart rate < 40 bpm) were managed in both groups with i.v ephedrine and atropine respectively. At the end of surgery, patients were returned to the supine position and the Co2 left in the peritoneal cavity was expelled by abdominal compression slowly. 0.25 % bupivacaine was injected again at the surgical incisions. Esmolol and Mgso4 infusions were stopped and discarded at end of the procedure, which was marked at the end of skin closure and wound coverage. Anaesthesia was discontinued and 100 % oxygen was administrated. Reversal of muscle relaxants by i.v neostigmine 0.04-0.08 mg/kg and atropine 0.02 mg/kg, and then oral secretion was suctioned and the patients were extubated fully awake after return of the protective airway reflexes with full muscle power. Times passed from end of procedure till spontaneous eye opening (from cessation of infusions till spontaneous eye opening), extubation, tongue protrusion, and patient's ability to mention name were recorded. Duration of surgery (time from skin incision till end of procedure) and duration of anaesthesia (time from induction till shifting the patients from operating table to the PACU) were also recorded.
Patients were transferred to the postanesthesia care unit (PACU) where heart rate, arterial blood pressure, respiration, and temperature were continuously monitored by a nurse blind to the study deign to avoid bias. Postoperative pain management included 1 g of paracetamol IV at 8 hr. Assessed of postoperative pain was done using pain numerical rating scale (NRS) on immediate arrival to PACU and every 30 mins for the first 2 hours afterwards. NRS is a (0-10) scale, where (0) denotes no pain, whereas (10) refers to maximal pain imagined. Fentanyl (25 μg) IV was used when NRS exceeded 4. Times to first rescue analgesia and total amount of fentanyl consumed were recorded. Recue antiemetic ondansetron (4 mg) IV was given for nausea lasting > 5 min (persistent) or vomiting and repeated as required. Total dose of ondansetron was noted.
The White-song scoring system a more up to date quick track scoring framework incorporating fundamental fast track variables like physical steadiness, vitals and consciousness level has been proposed to evaluate the recovery profile. Furthermore it involved assessment of adverse events like postoperative pain and vomiting, which were unfortunately missed by the modified Aldrete score. A minimum score (12 / 14) should be established prior to patient safe fast-tracked. It was evaluated on immediate arrival to PACU and every 30 mins for the first 2 hours afterwards. Patients reached White-Song score 12 + NRS < 4 were discharged from PACU. Length of stay in PACU till discharge were also recorded
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- 60 patients aged 20-65 years of both sexes, of American society of Anesthesiologists (ASA) physical status I and II planned for ambulatory laparoscopic cholecystectomy under general anaesthesia were engaged to this study. * Group (E): (Esmolol group) received loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery. * Group (M): (Magnesium sulphate group) received loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery.
| Arm | Type | Receives |
|---|---|---|
| Group E | Active comparator | Drug: EsmololEsmolol group: patients received loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery |
| Group M | Active comparator | Drug: Magnesium sulfateMagnesium sulphate group: patients received loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery. |
Who may qualify
- Ages
- 20 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- patients aged 20-65 years of both sexes
Key exclusion criteria (5 listed)
- patients on chronic use or known allergic to the study drugs
- body mass index >35 kg/m2,
- significant organ dysfunction, cardiac dysrhythmias, neuromuscular diseases
- liver or renal disease,
- known asthma or reactive airway diseases.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Esmololloading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery. | Drug | Group E |
| Magnesium sulfateloading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery. | Drug | Group M |
Primary outcome
times needed for spontaneous eye opening
Time frame: immediately postoperative
time passed from end of procedure until the patient open his eyes
1 secondary outcome
total amount of intraoperative fentanyl consumption
Time frame: immediately postoperative
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 May 2023.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Esmolol and Magnesium sulfate in people with Esmolol Adverse Reaction, run by Alexandria University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
times needed for spontaneous eye opening (time frame: immediately postoperative). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2023.